Browse > Article
http://dx.doi.org/10.5483/BMBRep.2022.55.12.136

Split genome-based retroviral replicating vectors achieve efficient gene delivery and therapeutic effect in a human glioblastoma xenograft model  

Moonkyung, Kang (Graduate School of New Drug Discovery and Development, Chungnam National University)
Ayoung, Song (Institue of Molecular Biology, Inje University)
Jiyoung, Kim (Graduate School of New Drug Discovery and Development, Chungnam National University)
Se Hun, Kang (Research Institute and Hospital, National Cancer Center of Korea)
Sang-Jin, Lee (Research Institute and Hospital, National Cancer Center of Korea)
Yeon-Soo, Kim (Graduate School of New Drug Discovery and Development, Chungnam National University)
Publication Information
BMB Reports / v.55, no.12, 2022 , pp. 615-620 More about this Journal
Abstract
The murine leukemia virus-based semi-retroviral replicating vectors (MuLV-based sRRV) had been developed to improve safety and transgene capacity for cancer gene therapy. However, despite the apparent advantages of the sRRV, improvements in the in vivo transduction efficiency are still required to deliver therapeutic genes efficiently for clinical use. In this study, we established a gibbon ape leukemia virus (GaLV) envelope-pseudotyped semi-replication-competent retrovirus vector system (spRRV) which is composed of two transcomplementing replication-defective retroviral vectors termed MuLV-Gag-Pol and GaLV-Env. We found that the spRRV shows considerable improvement in efficiencies of gene transfer and spreading in both human glioblastoma cells and pre-established human glioblastoma mouse model compared with an sRRV system. When treated with ganciclovir after intratumoral injection of each vector system into pre-established U-87 MG glioblastomas, the group of mice injected with spRRV expressing the herpes simplex virus type 1-thymidine kinase (HSV1-tk) gene showed a survival rate of 100% for more than 150 days, but all control groups of mice (HSV1-tk/PBS-treated and GFP/GCV-treated groups) died within 45 days after tumor injection. In conclusion, these findings sug-gest that intratumoral delivery of the HSV1-tk gene by the spRRV system is worthy of development in clinical trials for the treatment of malignant solid tumors.
Keywords
Cancer; Gene delivery; Gene therapy; Glioma; Replicating retroviral vector;
Citations & Related Records
연도 인용수 순위
  • Reference
1 von Kalle C, Kiem HP, Goehle S et al (1994) Increased gene transfer into human hematopoietic progenitor cells by extended in vitro exposure to a pseudotyped retroviral vector. Blood 84, 2890-2897    DOI
2 Bauer TR Jr, Miller AD and Hickstein DD (1995) Improved transfer of the leukocyte integrin CD18 subunit into hematopoietic cell lines by using retroviral vectors having a gibbon ape leukemia virus envelope. Blood 86, 2379-2387    DOI
3 Kiem HP, Heyward S, Winkler A et al (1997) Gene transfer into marrow repopulating cells: comparison between amphotropic and gibbon ape leukemia virus pseudotyped retroviral vectors in a competitive repopulation assay in baboons. Blood 90, 4638-4645    DOI
4 Gambhir SS, Herschman HR, Cherry SR et al (2000) Imaging transgene expression with radionuclide imaging technologies. Neoplasia 2, 118-138    DOI
5 Cao F, Li J, Li A, Fang Y and Li F (2013) One-stage laparoscopic resection for a large gastric gastrointestinal stromal tumor and synchronous liver metastases following preoperative imatinib therapy: a case report. Oncol Lett 5, 1233-1236    DOI
6 Sun XX and Yu Q (2015) Intra-tumor heterogeneity of cancer cells and its implications for cancer treatment. Acta Pharmacol Sin 36, 1219-1227 
7 Garcia-Rodriguez L, Abate-Daga D, Rojas A, Gonzalez JR and Fillat C (2011) E-cadherin contributes to the bystander effect of TK/GCV suicide therapy and enhances its antitumoral activity in pancreatic cancer models. Gene Ther 18, 73-81 
8 Kakinoki K, Nakamoto Y, Kagaya T et al (2010) Prevention of intrahepatic metastasis of liver cancer by suicide gene therapy and chemokine ligand 2/monocyte chemoattractant protein-1 delivery in mice. J Gene Med 12, 1002-1013    DOI
9 Muruve DA (2004) The innate immune response to adenovirus vectors. Hum Gene Ther 15, 1157-1166    DOI
10 Sun Y, Finger C, Alvarez-Vallina L, Cichutek K and Buchholz CJ (2005) Chronic gene delivery of interferon-inducible protein 10 through replication-competent retrovirus vectors suppresses tumor growth. Cancer Gene Ther 12, 900-912    DOI
11 Logg CR, Logg A, Tai CK, Cannon PM and Kasahara N (2001) Genomic stability of murine leukemia viruses containing insertions at the Env-3' untranslated region boundary. J Virol 75, 6989-6998    DOI
12 Logg CR, Tai CK, Logg A, Anderson WF and Kasahara N (2001) A uniquely stable replication-competent retrovirus vector achieves efficient gene delivery in vitro and in solid tumors. Hum Gene Ther 12, 921-932    DOI
13 Wang WJ, Tai CK, Kasahara N and Chen TC (2003) Highly efficient and tumor-restricted gene transfer to malignant gliomas by replication-competent retroviral vectors. Hum Gene Ther 14, 117-127    DOI
14 Tai CK, Wang WJ, Chen TC and Kasahara N (2005) Single-shot, multicycle suicide gene therapy by replication-competent retrovirus vectors achieves long-term survival benefit in experimental glioma. Mol Ther 12, 842-851    DOI
15 Qiao J, Moreno J, Sanchez-Perez L et al (2006) VSV-G pseudotyped, MuLV-based, semi-replication-competent retrovirus for cancer treatment. Gene Ther 13, 1457-1470    DOI
16 Trajcevski S, Solly SK, Frisen C, Trenado A, Cosset FL and Klatzmann D (2005) Characterization of a semi-replicative gene delivery system allowing propagation of complementary defective retroviral vectors. J Gene Med 7, 276-287    DOI
17 Johann SV, van Zeijl M, Cekleniak J and O'Hara B (1993) Definition of a domain of GLVR1 which is necessary for infection by gibbon ape leukemia virus and which is highly polymorphic between species. J Virol 67, 6733-6736    DOI
18 Wilson CA, Farrell KB and Eiden MV (1994) Properties of a unique form of the murine amphotropic leukemia virus receptor expressed on hamster cells. J Virol 68, 7697-7703    DOI
19 Kavanaugh MP, Miller DG, Zhang W et al (1994) Cell-surface receptors for gibbon ape leukemia virus and amphotropic murine retrovirus are inducible sodium-dependent phosphate symporters. Proc Natl Acad Sci U S A 91, 7071-7075    DOI
20 Miller DG and Miller AD (1994) A family of retroviruses that utilize related phosphate transporters for cell entry. J Virol 68, 8270-8276    DOI
21 Wilson CA, Eiden MV, Anderson WB, Lehel C and Olah Z (1995) The dual-function hamster receptor for amphotropic murine leukemia virus (MuLV), 10A1 MuLV, and gibbon ape leukemia virus is a phosphate symporter. J Virol 69, 534-537    DOI
22 Liu M and Eiden MV (2011) The receptors for gibbon ape leukemia virus and amphotropic murine leukemia virus are not downregulated in productively infected cells. Retrovirology 8, 53 
23 Bunnell BA, Kluge KA, Lee-Lin SQ et al (1999) Transplantation of transduced nonhuman primate CD34+ cells using a gibbon ape leukemia virus vector: restricted expression of the gibbon ape leukemia virus receptor to a subset of CD34++ cells. Gene Ther 6, 48-56    DOI
24 Horn PA, Topp MS, Morris JC, Riddell SR and Kiem HP (2002) Highly efficient gene transfer into baboon marrow repopulating cells using GALV-pseudotype oncoretroviral vectors produced by human packaging cells. Blood 100, 3960-3967    DOI
25 Movassagh M, Boyer O, Burland MC, Leclercq V, Klatzmann D and Lemoine FM (2000) Retrovirus-mediated gene transfer into T cells: 95% transduction efficiency without further in vitro selection. Hum Gene Ther 11, 1189-1200    DOI